Catalyst
Monitor for updates on dosing recommendations, safety results, and efficacy data as the trial progresses.
Date
June 20, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.